Protagonist Therapeutics (PTGX) FDA announcement summary

Introduction and purpose

• ICOTYDE (icotrokinra) received US FDA approval for moderate-to-severe plaque psoriasis in adults and pediatric patients 12+ years old weighing at least 40 kg who are candidates for systemic therapy or phototherapy.

• ICOTYDE is the first and only oral peptide-targeted therapy blocking the IL-23 pathway by targeting the IL-23 receptor, distinguishing it from injectable antibodies.

Details of approval or decision

• FDA approval was granted in March 2026 for ICOTYDE, formerly known as PN-235, based on four phase III studies involving about 2,500 patients, all meeting primary endpoints and demonstrating a favorable safety profile.

• The label is broad, covering adults and adolescents, high-impact disease sites, and includes head-to-head superiority data versus Sotyktu and comparisons with other therapies.

• ICOTYDE offers the convenience of a once-daily oral pill with efficacy comparable to injectable biologics.

Impact on industry and stakeholders

• ICOTYDE provides a needle-free, once-daily oral alternative to injectable biologics, potentially expanding the market and attracting patients avoiding injections.

• The approval triggers a $50 million milestone payment and initiates a royalty stream, with up to $580 million in future milestones and royalty rates up to 10% for annual sales over $4 billion.

• The partnership with J&J is exclusive to the IL-23 program; J&J handles commercialization and launch activities.

• Ongoing studies may expand ICOTYDE’s use to psoriatic arthritis, ulcerative colitis, and Crohn’s disease.